Director, Partnerships and Business Development
BiomeSense · Chicago, IL · 2 wk ago
On-siteBusiness Development$150k–$225k/yrFull-time
Key Responsibilities
- Translate emerging market trends into strategic planning for academic, biotech & pharma partnership growth
- Identify gaps in partnership approach & develop solutions for a scientific audience
- Work with research, hardware, operations & bioinformatics to execute near- and long-term partnership strategies
- Develop scientifically compelling collateral to communicate BiomeSense’s value proposition to new partners
- Build a partnership-tracking system and KPIs for academic and clinical collaborations
- Serve as primary partner liaison with academic researchers, oncology investigators & industry partners conducting interventional or translational studies
- Negotiate study agreements, manage IRB approvals & deliver results through creative partnerships that align incentives
- Translate microbiome and biomarker breakthroughs into further commercial opportunities and compelling content that builds partner and investor confidence
Qualifications
- 5+ years in a life sciences discipline in business development roles; startup experience preferred
- Track record managing academic or clinical research partnerships in translational medicine or biomarker discovery
- Proven ability to build systems and processes from scratch, including OKR tracking
- Knowledge of microbiome science, translational research & academic research
- Credible relationship builder with academic investigators, research administrators & industry partners
- Ability to translate complex science into compelling partnership narratives
- Self-starter with a collaborative, confident, humble and adaptable approach
About BiomeSense
BiomeSense is a life sciences startup building novel technologies (GutLab, MetaBiome) to transform gut microbiome biomarker discovery & translation. Our partners include UCSF, UCSD, NIH & the University of Chicago. We are backed by LabCorp Ventures, Bluestein Ventures, Seerave Foundation & Emil Capital Partners.